SAN DIEGO--(BUSINESS WIRE)--MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.
